Facing Cancer Drug Shortage, U.S. Relies on Banned Chinese Plant

  • Chinese factory on FDA’s ban list after failing inspection
  • 15 exempted products still allowed in the U.S. market

Tainted Meds Versus No Meds at All: The FDA's Compromise

Last September, U.S. regulators faced a dilemma: whether to allow importation of drug ingredients from a Chinese factory with a history of poor quality controls, or face shortages of treatments for American cancer patients.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.